The finding came from the NHLBI-funded Bypass Angioplasty Revascularization Investigation (BARI). The multicenter, international, randomized trial studied patients who needed a first revascularization because of severe ischemia with obstructions in two or more major coronary arteries. Over 5 years, patients with diabetes mellitus who were on drug therapy had a significantly lower (p=0.002) mortality rate with CABG, compared with percutaneous transluminal coronary angioplasty (PTCA). The 5-year CABG mortality rate was 19 percent, compared with 35 percent for PTCA. By contrast, in patients without diabetes and in those with diabetes but not on drug treatment, the 5-year mortality rates for CABG and PTCA were both about 9 percent.
Expert Rita Rastogi Kalyani, MD, MHS, is an assistant professor at Johns Hopkins School of Medicine.
Q: What is prediabetes, and how can I stop it from becoming full-blown diabetes?
A: Prediabetes means your blood sugar (glucose) level is above normal, but not high enough to be considered diabetes. The higher level means your body is starting to have trouble using the hormone insulin, which normally moves glucose from the blood into your body's cells. Without insulin working properly, glucose...
The higher death rate for PTCA was not due to complications of the procedure itself. Those with diabetes are known to have an excessive cardiovascular risk and a higher mortality rate was expected for them, regardless of revascularization procedure. However, the excess mortality with PTCA had not been anticipated.
BARI's results indicate that CABG should be the preferred treatment for patients with diabetes on drug or insulin therapy who have multivessel coronary artery disease and need a first coronary revascularization. These results have a significant impact on the clinical care of these patients.
Coronary revascularization plays an important role in the treatment of clinically severe coronary artery disease. The two most commonly used methods of revascularization are CABG and PTCA. PTCA is a catheter-based nonsurgical approach that directly targets coronary obstructions by dilation of the vessel at the point of obstruction. The process is accompanied by local vascular injury and subsequent healing. The extent of injury and the healing process may be different in diabetic and nondiabetic patients. Not all lesions can be dilated, due largely to technical reasons. CABG is a major operation, requiring opening of the chest. It provides a new channel, with a lumen frequently larger than the native, diseased lumen. There is no instrumentation of the local lesion and, therefore, no related vascular injury. While both treatments alleviate the effects of coronary artery disease, they do not correct or alter the natural course of the disease.